Upregulation of a lymphoid serine protease in kidney allograft recipients

Kidney International
G Sunder-PlassmannC P Worman

Abstract

The presence of a putative, cytotoxicity-linked lymphoid serine esterase (SE) has been studied in 79 kidney graft recipients. Peripheral blood lymphocytes (PBL) bearing an N-alpha-benzyloxy carbonyl-L-lysine thiobenzyl ester (BLT)-specific SE were evaluated by a novel cytochemical staining method. A characteristic of post-allograft patients was an increased presence of SE containing granules in PBL. In 46 patients with stable graft function SE + PBL were 33.41 +/- 10.34% (controls: 26.30 +/- 5.22%, P less than 0.0025), SE + CD4+ 4.32 +/- 3.85% (controls 2.13 +/- 1.52%, P less than 0.0025) and SE + CD8+ T cells 47.68 +/- 18.64% (controls: 28.50 +/- 6.50%, P less than 0.0005). In those graft recipients undergoing a rejection episode a marked upregulation of SE activity could be observed when compared to the stable graft group: SE + PBL were 59.91 +/- 10.89% (P less than 0.0005), SE + CD8+ 74.30 +/- 10.79% (P less than 0.0005) and SE + CD4+ T cells 28.56 +/- 13.50% (P less than 0.0005). In 10 cases this increase of SE activity was observed with a time lag of up to 37 days prior to the onset of clinical or biopsy proven rejections, promptly decreasing in response to methylprednisolone antirejection therapy. In patients with recurre...Continue Reading

References

Jun 26, 1975·Nature·J Ferluga, A C Allison
Jun 12, 1975·The New England Journal of Medicine·T B StromG J Busch
Jan 1, 1986·Journal of Cellular Biochemistry·E R Podack
Sep 1, 1987·The Journal of Experimental Medicine·H Takayama, M V Sitkovsky
Apr 1, 1989·Kidney International·T B Strom, V E Kelley
Oct 1, 1986·Transplantation·E von WillebrandP Häyry
Jan 1, 1987·Transplantation·W C WaltzerF T Rapaport
Feb 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·H K GershenfeldI L Weissman
Mar 1, 1988·Immunological Reviews·E R PodackH Hengartner
Mar 1, 1988·Immunological Reviews·W ClarkB Torbett
Aug 20, 1987·The New England Journal of Medicine·F H Bach, D H Sachs
Apr 1, 1985·Nature·M S Pasternack, H N Eisen
Feb 1, 1984·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J L CordellD Y Mason
Jul 1, 1983·Scandinavian Journal of Immunology·G TufvesonL Frödin
Sep 1, 1984·Kidney International·T B Strom
Mar 15, 1980·Cellular Immunology·N GaliliB Nordenskjöld

❮ Previous
Next ❯

Citations

Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·J StrehlauT B Strom
Mar 1, 1997·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·P C WeverI J ten Berge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.